🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#lungcancer #lcsm KRASKickers #kras FLASCO OLACANCER Memorial Cancer Institute Memorial Healthcare System

MYC in cancer: from undruggable target to clinical trials | Nature Reviews Drug Discovery nature.com/articles/s4157…

From the February issue: The Evolutionary Forest of #PancreaticCancer aacrjournals.org/cancerdiscover… By Katelyn Mullen, Ben Raphael, Chris Iacobuzio, and colleagues. MSKCC Center for Pancreatic Cancer Research Memorial Sloan Kettering Cancer Center

very honored to participate in the training of future #lungcancer leaders #LCSM

Thanks to KRASKickers for te opportunity to discuss about biomarkers with their community! Thanks TerriConneran for the fantastic discussion! Testing Testing Testing! The James Ohio State Medical Oncology International Society of Liquid Biopsy

Targeted protein degradation for cancer therapy | Nature Reviews Cancer nature.com/articles/s4156…

Congratulations to Sandra Misale, PhD, recipient of the 2025 Cancer Discovery Early Career Award, which recognizes the outstanding contributions of #earlycareer investigators. Learn more: brnw.ch/21wSfdp #AACR25 Johns Hopkins Medicine Johns Hopkins Kimmel Cancer Center AACR

This is the way to start the day!! #AACR25 Doc (Shokat ) that found the Pocket to kick the first KRAS .. #KRASKicker 💥

Dr Shokat talk at opening plenary at #AACR25 on how progress in studying #KRAS, historically known as ‘undruggable’, led to developing drugs to target it. Never say never… The impossible CAN be possible! KRASKickers #LCSM

#AACR25 session today ND01 - AMG 410: An H/NRAS-sparing pan-KRAS inhibitor with dual GTP(on)/GDP(off)-state activity for the treatment of diverse KRAS-mutant tumors A FIH study with AMG 410 is planned CRC, PDAC, NSCLC) G12D, G12V, G13D abstractsonline.com/pp8/#!/20273/p… KRASKickers

conclusion slide many slides of interest including KRAS targets & their responses as well as combinatorial options (EGFRi & anti-PD-1) KRASKickers #AACR25

Brilliant presentation by Katie Arbour MSKCC of the RMC9805 data!#AACR25 MD Anderson Cancer Center

Christine Lovly, MD, PhD, FASCO AACR IASLC Very exciting early signals for JYP0322 at #AACR25 — especially promising that no DLTs were observed and MTD wasn't reached during dose escalation. Also interesting that patients with stable CNS metastases were eligible — curious to see more on intracranial outcomes as data

SY08 - Developments in RAS Signaling Inhibition: Bench to Bedside Frank McCormick! Piro Lito! Sandra Misale! abstractsonline.com/pp8/#!/20273/s… KRASKickers Sandra Misale

So proud of you & the #KickKRAS progress you’re making!! KRASKickers

Online now concurrent with the #AACR25 oral presentation by Cancer Discovery Early Career Award Winner Sandra Misale: Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations brnw.ch/21wSh8j

Thank you for all that it takes to make this happen! #AACR25 hardworking folks we appreciate you !

Advances in ctDNA assays enhance early relapse detection in lung cancer — sessions at #ASCO25 will showcase these data and I look forward to seeing the updates on MRD! Penn Medicine MD Penn Medicine Penn Medicine - Abramson Cancer Center ASCO OncoAlert Martin Reck

Big Ben of thoracic oncology teaches us after recent failures how to make ADCs great again! Upfront combinations of Dato-dxd w pembro+_ platinum in TROPION Lung02 seem feasible although some AE concerns- activity enriched by NMR QCS and might be the way forward to enrich patient

BBO-10203 inhibits tumor growth without inducing hyperglycemia by blocking RAS-PI3Kα interaction | Science science.org/doi/10.1126/sc…